Head

profile_image
Dr. Hedda Wardemann
Phone:+49 6221 42 1270

Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280 69120 Heidelberg

dkfz

Molecular Immunology

Molecular Immunology

Dr. Hedda Wardemann studied Immunology at the Biology Faculty of the Albert Ludwig University in Freiburg, Germany. She received her PhD in 2001 with a thesis work performed at the Max Planck Institute for Immunobiology on the function of the spleen for the development of B1 cells in mice. She started her postdoctoral training in 2002 at the Rockefeller University in New York, USA, where she focused her interest on B cell tolerance in human. She was promoted Assistant Professsor in 2003 at the Rockefeller University and was appointed Independent Junior Research Group Leader at the Max Planck Institute for Infection Biology in 2006. In 2014 she has been appointed to the German Cancer Research Center.

Research interests

The adaptive immune system is characterized by the diversity of its antigen-receptors and the formation of memory. Two random mechanisms generate B cell antigen-receptor diversity. The first one is somatic immunoglobulin (Ig) gene recombination by which functional Ig genes are assembled from a large number of germline encoded small Ig heavy and Ig light chain gene segments during the early stages of B cell development in bone marrow.

The second mechanism is somatic mutations of functionally rearranged Ig genes in B cells, which have been activated by antigen in the presence of T cell help. The random nature of the two processes generates antibodies against a plethora of diverse pathogens, but the downside is the production of potentially harmful autoantibodies and antibodies directed against non-pathogenic foreign antigens or microbes. Thus, constant shaping of the antibody repertoire by positive and negative selection during B cell development and differentiation is essential to allow the generation of highly efficient and specific humoral immune responses to invading pathogens while maintaining tolerance to self and non-pathogenic foreign microbes, e.g. commensal bacteria in the gut.

The overall goal of our research is to establish how antibody diversity is shaped by self- and foreign antigen-driven selection in health and disease. To measure the diversity of the antibody repertoire we have previously developed a strategy that allows the efficient cloning and expression of antibodies from single isolated B cells. Fluorescent activated cell sorting is used to isolate single cells belonging to defined B cell subpopulations from peripheral blood, organs or tissues. Further, the strategy allows the isolation of antigen-specific cells if fluorescently labeled antigen is used in the isolation strategy. Research in our group is focused around this technology. We are currently investigating the human and murine antibody repertoire under normal conditions, in systemic autoimmunity, under chronic inflammatory conditions and in response to vaccination and infection.

Perspective

The long-term goal of our laboratory is

  1. to define additional tolerance checkpoints in humans
  2. to enumerate the frequency of developing self-reactive antibodies in the periphery and
  3. to study how the immune system keeps the balance between an efficient antibody response to invading pathogens and prevention of autoimmunity.
 
loading content